Rethinking the Role of Intellectual Property Rights in Pharmaceutical Industry of Saudi Arabia
DOI:
https://doi.org/10.56042/jipr.v28i1.536Keywords:
Pharmaceutical Industry, Intellectual Property Rights, GDP, IP Laws, Special 301 Report, Watch-List, Non- Watch-List Countries, Patents, Trademarks, National Transformation Program (NTP) 2020Abstract
This article attempts to analyze the role of pharmaceutical industry intellectual property rights and comparison of Saudi
Arabia with other watch list and non-watch list countries according to the US trade representative Special 301 Report. Time
series data (2001-2020) is used to compare and analyze the data using simple regression. Also, Covariance analysis and least
square method are used to compare the data of other countries with Saudi Arabia. It was found that there is significant
impact of the Saudi pharmaceutical industry on the GDP, and it has also developed its IPRs, patents, trademarks, and trade
secrets. Macroeconomic outcomes are strongly tied to the enforcement of IP laws in both watch list and non-watch list
countries. Therefore, it is important to underline the differences in IPR in these countries. This will help us to test whether
empirical results at macro-level -that are alleged to be led by the stronger or weak IP laws – hold in the actual IP Law
enforcements. In this paper, we investigate the differences and similarities in IP laws in these selected countries.